| (a) | by deleting item (3) of paragraph 1 and substituting the following item:| “(3) | 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine (also known as 4-bromo-2,5-dimethoxyphenethylamine or 2C-B) and its bromo and dimethoxy positional isomers in the phenyl ring”; |
|
|
| (b) | by deleting items (12) and (13) of paragraph 1 and substituting the following items:| “(12) | 2,5-Dimethoxy-4,α-dimethylphenethylamine (also known as 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM) | | (13) | 2,5-Dimethoxy-α-methylphenethylamine (also known as 2,5-Dimethoxyamphetamine) and its dimethoxy positional isomers in the phenyl ring”; |
|
|
| (c) | by deleting item (26) of paragraph 1 and substituting the following item:| “(26) | p-Methoxy-α-methylphenethylamine (also known as 4‑methoxyamphetamine or para‑methoxyamphetamine) and its methoxy positional isomers in the phenyl ring”; |
|
|
| (d) | by inserting, immediately after the word “bupropion” in paragraph 15, the words “and 2-(Diethylamino)-1-phenyl-1-propanone (also known as amfepramone or diethylpropion or diethylcathinone)”; |
| (e) | by deleting item (1) of paragraph 15 and substituting the following items:| “(1) | 1-(1,3-Benzodioxol-5-yl)-2-(benzylamino)propan-1-one (also known as 3,4-Methylenedioxy-N-benzylcathinone or BMDP) | | (1A) | 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-propanone (also known as bk-MDDMA) | | (1B) | 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (also known as ethylone or 3,4-Methylenedioxy-N-ethylcathinone or bk-MDEA or MDEC)”; |
|
|
| (f) | by deleting items (8A) of paragraph 15 and substituting the following items:| “(8A) | 2-(Benzylamino)-1-(4-methylphenyl)propan-1-one (also known as Benzedrone); | | (8AA) | 1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brephedrone or 4‑BMC)”; |
|
|
| (g) | by deleting item (10A) of paragraph 15 and substituting the following items:| “(10A) | 2-(Ethylamino)-1-(4-ethylphenyl)propan-1-one (also known as 4-Ethylethcathinone) | | (10B) | 2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC)”; |
|
|
| (h) | by inserting, immediately after item (17) of paragraph 15, the following item:| “(17A) | 2-(Methylamino)-1-(4-methylphenyl)butan-1-one (also known as 4-Methylbuphedrone or 4‑Me‑MABP)”; |
|
|
| (i) | by deleting item (19) of paragraph 15 and substituting the following item:| “(19) | 2-(Methylamino)-1-phenylpentan-1-one (also known as pentedrone or α-Methylaminovalerophenone)”; |
|
|
| (j) | by inserting, immediately after item (22) of paragraph 15, the following item:| “(22A) | 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Methyl-α-pyrrolidinohexanophenone or MPHP)”; |
|
|
| (k) | by inserting, immediately after item (23) of paragraph 15, the following item:| “(23A) | 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as 4-Methyl-α-pyrrolidinopropiophenone or 4‑MePPP)”; |
|
|
| (l) | by deleting item (2B) of paragraph 17 and substituting the following item:| “(2B) | N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as MAB-CHMINACA or ADB‑CHMINACA)”; |
|
|
| (m) | by deleting items (2J) and (2K) of paragraph 17 and substituting the following items:| “(2J) | N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as PX-2 or 5-Fluoro-APP-PINACA) and its fluoro positional isomers in the pentyl group | | (2K) | N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as PX-1 or 5-Fluoro-APP-PICA) and its fluoro positional isomers in the pentyl group”; |
|
|
| (n) | by inserting, immediately after item (10A) of paragraph 17, the following item:| “(10B) | 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and its dichloro positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring”; |
|
|
| (o) | by inserting, immediately after item (20) of paragraph 17, the following item:| “(20A) | 5-Fluoropent-1-yl-N-naphthalen-1-yl-1H-indole-3-carboxamide (also known as CBM-2201, 5-Fluoro-NNEI, 5F-NNEI or MN-24F) and its fluoro positional isomers in the pentyl group”; |
|
|
| (p) | by deleting item (26) of paragraph 17 and substituting the following item:| “(26) | 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol (for example HU-210, HU-211)”; |
|
|
| (q) | by inserting, immediately after item (28B) of paragraph 17, the following item:| “(28BA) | Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}-3-methyl-L-valinate or MDMB‑CHMICA)”; and |
|
|
| (r) | by inserting, immediately after item (36) of paragraph 17, the following items:| “(36A) | Naphthalen-1-yl 5-fluoropent-1-yl-1H-indole-3-carboxylate (also known as NM-2201 or CBL-2201) and its fluoro positional isomers in the pentyl group | | (36B) | Naphthalen-1-yl[1-(pent-1-yl)-1H-indazol-3-yl]methanone (also known as THJ-018)”. |
|
|
